StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Strong top-line growth, raised full-year guidance, and clear near-term catalysts (Phase 3 readouts; Soleno integration) tend to attract buyers and could push NBIX higher in the near term.
What happened, with direct paths to the underlying reporting
Neurocrine reported Q3 2026 revenue of $1.123B, up 41% YoY, led by INGREZZA with $801M in net product sales. The company raised full-year INGREZZA guidance to $2.90–$2.925B and highlighted progress across CRENESSITY and VYKAT XR, plus upcoming Phase 3 reads for osavampator and direclidine. The Soleno acquisition closed in 2026, adding IP and expanding the VYKAT XR franchise.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.